
- Volume 0 0
CLARINEX MAKER SUES OVER GENERICS
A bid by a generic company in Largo,Fla, to produce a generic version of theallergy medication Clarinex (desloratadine)has been blocked by a lawsuitfrom Schering-Plough Corp, makers ofthe brand drug. The pharmaceuticalcompany has sued GeoPharma Inc andits subsidiary, Belcher Pharmaceuticals,in federal court in New Jersey forpatent infringement. The suit is tied toBelcher's filing for a generic version ofClarinex 5-mg tablets with the FDA.
Schering's lawsuit also names 12other pharmaceutical companies thatfiled for rights to generic Clarinex atthe same time as Belcher. Sales ofClarinex in 2005 reached $325 million,and, although competition was expectedto be tight, Mihir Taneja, chief executiveof GeoPharma, was surprisedthat so many others were lining up tomake generic Clarinex as well. He andthe other defendants are claiming thattheir versions of the allergy drug arebioequivalent to the brand version butdo not infringe on Schering's patent,which expires in June 2007. The FDAcan approve the generic filings ifthe complaint is not resolved in 30months.
Articles in this issue
almost 19 years ago
Cold Sore Outbreak?almost 19 years ago
Compounding with Commercial Drugs Can Cause Errorsalmost 19 years ago
compounding HOTLINEalmost 19 years ago
can you READ these Rxs?almost 19 years ago
Time to Share Accountabilityalmost 19 years ago
nacds SPEAKS OUT: One Voice Is Critical in Pharmacy Todayalmost 19 years ago
Use of Probiotics in the Management of Antibiotic-associated Diarrheaalmost 19 years ago
Labeling in Failure-to-Warn Casealmost 19 years ago
Ohio Prosecutors Fight Rx Abusealmost 19 years ago
Lean on Me: Help for the Impaired PharmacistNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.















































































































































































































